Say It Isn't So
I have just received a poignant email from a lymphoma patient who has been reading this blog.
She relates that she has learned that the pharmaceutical manufacturer of Zevalin has ceased marketing and promotion of this important radioimmunotherapy (RIT) medicine.
She wrote, "I just received my Zevalin. I may be the last person to receive this important drug".
The RIT medicines, Zevalin and Bexxar, are too valuable, indeed, life-saving, to be lost. We, the patients, are the only ones capable of saving these medicines. And how do we save them? By insisting on a consultation with a physician who is experienced and trained in administering RIT before deciding on a personal lymphoma treatment plan.
Say it isn't so.
Mort